Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

Blumendeller, Carolin; Boehme, Julius; Frick, Maximilian; Schulze, Martin; Rinckleb, Antje; Kyzirakos, Christina; Kayser, Simone; Kopp, Maria; Kelkenberg, Sabine; Pieper, Natalia; Bartsch, Oliver; Hadaschick, Dirk; Battke, Florian; Stenzl, Arnulf; Biskup, Saskia

Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

Autor(en):

Blumendeller, Carolin; Boehme, Julius; Frick, Maximilian; Schulze, Martin; Rinckleb, Antje; Kyzirakos, Christina; Kayser, Simone; Kopp, Maria; Kelkenberg, Sabine; Pieper, Natalia; Bartsch, Oliver; Hadaschick, Dirk; Battke, Florian; Stenzl, Arnulf; Biskup, Saskia

Tübinger Autor(en):

Stenzl, Arnulf

Erschienen in:

Journal For Immunotherapy of Cancer (2021), Bd. 9, Article e001406

Verlagsangabe:

Bmj Publishing Group

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1136/jitc-2020-001406

ISSN:

2051-1426